News brief­ing: Gy­ro­scope and Ta­laris set IPO terms; FDA grants ex­pand­ed nod to Chiesi's sick­le cell drug

In a week where two biotech IPOs were al­ready ex­pect­ed, an­oth­er two prospec­tive en­trants have set their de­but terms ahead of their launch lat­er this week.

Gy­ro­scope Ther­a­peu­tics and Ta­laris Ther­a­peu­tics each set IPO terms Mon­day morn­ing. Gy­ro­scope, based out of the UK, is plan­ning to of­fer 6.8 mil­lion ADSs at a price range of $20 to $22, while Ta­laris ex­pects to of­fer 8.8 mil­lion shares be­tween $16 and $18 each.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.